Drug Reimbursement, Biologics Exclusivity Should Be Part Of EU Trade Talks, PhRMA And BIO Say
Executive Summary
Branded drug industry representatives presented a number of recommendations for U.S. negotiating priorities in upcoming trade talks with the European Union at a May 30 public hearing.
You may also be interested in...
Efforts To Adopt Path-Breaking Pharmaceutical Global Trade Rules In TPP Remains Work-In-Progress
Efforts to get a major new trade bloc to adopt stronger pharmaceutical intellectual property rules, including a potential path breaking agreement on biologics data exclusivity remains a work-in-progress, trade negotiators said at the end of the 18th round of the Trans-Pacific Partnership talks. But hope still floats the diverse group of 12 countries might find compromise language.
Trans-Pacific Partnership Pact Set As Test Ground For Getting Biologics Data Exclusivity At National Levels
While much of the talk on data exclusivity for biologics in the Trans-Pacific Partnership has been on the 12-year window in U.S. law, sources said current thinking is to get the other nations to agree to approve their own standards within a set time frame and use it as a template for future free trade agreements.
NICE Rejects Avastin For Ovarian Cancer On Cost, Okays Lucentis
NICE has knocked back Avastin for ovarian cancer due to high cost, but Roche may have a plausible market strategy in place for the drug in the UK.